Clinical Trial Update: Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine [Phase 4]

View source ↗

Summary

A Phase 4 trial at UMC Utrecht investigates predicting electroconvulsive therapy response and reducing cognitive side-effects in major depressive disorder using…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Rivastigmine (Rivastigmine)

Snippet

Sponsor: UMC Utrecht | Conditions: Depressive Disorder | Phase 4 | Status: RECRUITING